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ABSTRACT
Background and aims Adenomatous polyposis coli
(APC) is a tumour suppressor gene mutated in the
germline of patients with familial adenomatous polyposis
(FAP) and somatically in most colorectal cancers. APC
mutations impair b-catenin degradation, resulting in
increased Wnt signalling. The most frequent APC
mutation is a codon 1309 truncation that is associated
with severe FAP. A previous study compared two mouse
models of intestinal tumorigenesis, Apc
R850X (Min) and
Apc
1322T (1322T), the latter a model of human codon
1309 changes. 1322T mice had more severe polyposis
but, surprisingly, these tumours had lower levels of
nuclear b-catenin than Min tumours. The consequences
of these different b-catenin levels were investigated.
Methods Enterocytes were isolated from 1322T and
Min tumours by microdissection and gene expression
proﬁling was performed. Differentially expressed Wnt
targets and other stem cell markers were validated using
quantitative PCR, in situ hybridisation and
immunohistochemistry.
Results As expected, lower nuclear b-catenin levels in
1322T lesions were associated with generally lower
levels of Wnt target expression. However, expression of
the Wnt target and stem cell marker Lgr5 was
signiﬁcantly higher in 1322T tumours than in Min
tumours. Other stem cell markers (Musashi1, Bmi1 and
the Wnt target Cd44) were also at higher levels in 1322T
tumours. In addition, expression of the Bmp antagonist
Gremlin1 was higher in 1322T tumours, together with
lower Bmp2 and Bmp4 expression.
Conclusions The severe phenotype caused by
truncation of Apc at codon 1322 is associated with an
increased number of stem cells. Thus, a submaximal
level of Wnt signalling favours the stem cell phenotype
and this may promote tumorigenesis. A level of Wnt
signalling exists that is too high for optimal tumour
growth.
INTRODUCTION
Adenomatous polyposis coli (APC) is a tumour
suppressor gene that is mutated in patients with
familial adenomatous polyposis and the majority of
sporadic colorectal cancers. It is a component of the
canonical Wnt signalling pathway, regulating the
transcription factor b-catenin. Truncation or loss of
APC disrupts the b-catenin degradation complex
leading to an increase in nuclear b-catenin levels
and aberrant expression of Wnt pathway target
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Signiﬁcance of this study
What is already known about this subject?
< Adenomatous polyposis coli (APC) is a tumour
suppressor gene mutated in the germline of
patients with familial adenomatous polyposis
and somatically in most colorectal cancers. Apc
mutations lead to increased levels of Wnt
signalling.
< The ‘just right’ model proposes that different
mutations in APC result in different levels of Wnt
pathway activation and differing levels of tumour
susceptibility, and that an intermediate level of
Wnt signalling is optimal for the initiation of
colorectal tumorigenesis.
< Two mouse models with different Apc mutations
causingproteintruncationsatcodon850(Min)and
1322 (1322T) show differences in the severity of
intestinal polyposis, with the 1322 truncation
causing more numerous and larger adenomas.
< This more severe phenotype is associated with
a submaximal level of active/nuclear b-catenin.
What are the new ﬁndings?
< Lower nuclear b-catenin in 1322T adenomas is
associated with mostly lower levels of Wnt target
expression.
< Conversely, expression of the Wnt target and
stem cell marker Lgr5 was signiﬁcantly higher in
1322T tumours than in Min tumours, and in
normal intestinal crypts from the former.
< Other stem cell markers (Musashi1, Bmi1 and the
Wnt target Cd44) were also at higher levels in
1322T tumours.
How might it impact on clinical practice in the
foreseeable future?
< Our ﬁndings suggest that higher levels of stem
cells in both normal tissue and adenomas cause an
increase in colorectal tumour numbers, size and
dysplasia. Quantifying stem cells may help to
predict the risk of colorectal tumours in humans.
< The 1322T mouse model of colorectal tumorigen-
esis has high numbers of stem cells and will make
a useful system to test novel therapies directed
speciﬁcally at cancer stem cells in the intestine.
< The conﬁrmation of the ‘just right’ hypothesis
provides valuable information about optimal levels
of Wnt signalling in tumorigenesis and suggests
that modulating Wnt levels either up or down may
alter tumorigenesis.
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Colon cancergenes. However, it has been difﬁcult to determine which of the
numerous Wnt target genes are primarily responsible for tumour
initiation.
The ‘just right’ model
1 2 proposes that different mutations in
APC result in different levels of Wnt pathway activation and
differing levels of tumour susceptibility. Few APC mutations
found in vivo result in absence of protein function, and it is
extremely rare to ﬁnd a colorectal cancer in which neither
mutant APC allele harbours a mutation after codon 1265.
Germline mutations resulting in APC proteins truncated at
codon 1309, for example, are relatively common and result in
more severe familial adenomatous polyposis than proteins
truncated at an earlier point. It is established that a 1309-trun-
cated APC protein retains some b-catenin binding and degrada-
tion activitydfor example, through the 20-amino acid b-catenin
binding repeat (20AAR) that it retainsdwhereas shorter
proteins do not.
34These ﬁndings suggest that an intermediate
level of Wnt signalling is optimal for the initiation of colorectal
tumorigenesis.
We recently tested this hypothesis by performing a detailed
phenotypic and molecular comparison of two Apc-mutant mice
on the C57BL6/J background: the Apc
R850X (Min) mouse model
which is heterozygous for a truncating mutation at codon 850
and the Apc
1322T (1322T) model which is heterozygous for an
allele functionally equivalent to the human 1309 mutation.
4 In
both animals, tumours usually develop when the wild-type
allele undergoes loss of heterozygosity by mitotic recombina-
tion. We found that the 1322T mouse did indeed develop more
severe polyposis, with more tumours developing at a faster rate
than in the Min model. The 1322T tumours, however, had much
lower levels of nuclear b-catenin.
The main physiological difference between the 1322Tand Min
intestines was the increased incidence of crypt ﬁssion in normal
and polyp tissue from the former. Crypt ﬁssion has been
proposed as a mechanism of early tumorigenesis
5 6 and may
therefore underlie the more rapid adenoma development seen in
the 1322T mice. It has been proposed
7 that crypt ﬁssion occurs
when stem cell numbers in a crypt exceed some threshold level.
In early colorectal adenomas it is plausible that the same model
applies, and that tumorigenesis is driven by increased numbers
of stem-like cells, leading to crypt ﬁssion and hence increased
adenoma size and number.
It has previously been difﬁcult to test the connection between
crypt ﬁssion, stem cells and tumorigenesis due to the lack of
accurate intestinal stem cell markers. However, recently there
has been a number of papers identifying putative stem cell
markers in the gastrointestinal tract. One of the most compel-
ling of these markers is Lgr5 (leucine-rich-repeat-containing G-
protein-coupled receptor 5), also known as Gpr49, a Wnt target
gene.
8 Lineage tracing experiments have shown that Lgr5-posi-
tive crypt base columnar (CBC) cells contribute to all epithelial
lineages in the intestine and that speciﬁc mutation of Apc in
Lgr5-positive CBC cells efﬁciently drives adenoma formation.
9
Indeed, single Lgr5-positive cells can generate crypt-like struc-
tures in vitro in speciﬁc culture conditions.
10 The function of the
Lgr5 protein itself, however, is not well understood in the
intestine and Lgr5 knockout mice die at neonatal stages due to
a tongue defect. Therefore it is likely that Lgr5 is purely a marker
that is co-expressed with unknown genes that confer the
intestinal stem cell phenotype.
11
Another intestinal stem cell marker veriﬁed using lineage
tracing experiments is the polycomb ring ﬁnger protein, Bmi1.
12
There are some differences between the Bmi1- and Lgr5-positive
cell populations, with Bmi1 being found predominantly at the
+4 crypt position rather than in CBCs and only towards the
proximal end of the small intestine. This raises the possibility of
more than one stem cell population existing in the small intes-
tine, although the different populations might overlap. The
neural RNA-binding protein Musashi1 (Msi1) is also found
speciﬁcally in the +4 cells but has not been investigated in great
detail.
13 14 CD44, like Lgr5, is a Wnt target gene and has been
proposed as an intestinal stem cell marker due to the capacity of
expressing cells to propagate tumours as xenografts.
15 16 Prom-
inin1 (CD133), which has also been shown to mark tumorigenic
cells in xenograft studies, is expressed in the same CBC cells as
Lgr5, but is also present in transit amplifying cells further up the
crypt, suggesting that it is not a strict stem cell marker.
17e20
In this study we have used expression proﬁling to gain clues
about the important differences in Wnt target expression
between tumours from 1322T and Min mice. In addition, we
have used multiple markers to examine the hypothesis that the
more severe tumorigenesis in 1322T than Min mice is driven by
higher numbers of stem-like cells in the former. The conclusions
support the notion that maintenance of a stem-like phenotype
in adenoma cells promotes tumorigenesis.
METHODS
Mouse breeding and collection of samples
All 1322T and Min animals were housed in the Barrier Unit of
Cancer Research UK, Clare Hall Laboratories and all work was
approved by the UK Home Ofﬁce and local ethics committee.
1322T or Min mice were sacriﬁced at a speciﬁed age or when
symptomatic (anaemic secondary to polyps or suffering rectal
prolapse). The intestinal tract was divided into four segments,
consisting of stomach, three equal lengths of small intestine
(proximal (SB1), middle (SB2), and distal (SB3)), and large
intestine. Each segment was ﬂushed with phosphate buffered
saline (PBS), opened longitudinally and laid out on ﬁlter paper.
The samples were ﬁxed in 10% neutral buffered formalin for
3 h and stored in 70% ethanol or embedded in OCT (Sigma,
St Louis, MO, USA) and snap frozen in liquid nitrogen.
Laser capture microdissection, extraction of RNA and
microarray analysis
Nine serial 8 mm cryosections were taken from OCT-embedded
intestine preparations. Every third section was stained with
H&E using standard protocols. The remaining sections were
incubated in ice-cold 70% ethanol for 2 min, cresyl violet
staining solution (1% cresyl violet acetate, 50% ethanol) for 30 s
and washed brieﬂy in 70% ethanol followed by 100% ethanol.
After air drying for 1e2 min, laser capture microdissection was
carried out using the PALM system. Cell types were distin-
guished in the serial H&E sections and areas of the adenomas
containing enterocytes with no Paneth cells were selected. The
same area was captured from 5e6 sections for each tumour and
the RNA was extracted using the PicoPure RNA extraction kit
(Applied Biosystems, Life Technologies, Carlsbad, California,
USA) and treated with RNase-free DNase I (Qiagen, Hilden,
Germany). RNA quality was assessed on a Bioanalyzer (Agilent,
Santa Clara, CA, USA). Three 1322T and three Min tumour
samples were sent to the Paterson Institute Microarray Service
where they were hybridised to GeneChip Mouse Exon 1.0 ST
Arrays (Affymetrix, Santa Clara, CA, USA). Output Cel ﬁles
were analysed using the R statistical programme with the robust
multichip average (RMA) method, which is implemented in the
BioConductor package ‘Affy’. Differentially expressed genes
were then identiﬁed using the linear models of microarray
analysis (LIMMA) package.
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Colon cancerArray validation by quantitative PCR (Q-PCR)
RNA was extracted from microdissected adenoma tissue as
above and cDNA was synthesised using the Stratagene Afﬁnity
script Q-PCR kit (Applied Biosystems, Life Technologies,
Carlsbad, CA, USA). Q-PCR was carried out on a 7900 Fast
Real-time PCR machine using pre-optimised Taqman probes
and primers (Applied Biosystems), and normalised to Gapdh.
Analysis was carried out using the standard ΔΔCt method.
In situ hybridisation
mRNA in situ hybridisation (ISH) was carried out using 4 mm
serial sections from formalin-ﬁxed parafﬁn-embedded mouse
intestines. Riboprobes were generated for each gene of interest.
Speciﬁcally for the Lgr5 probe, a 562 bp long PCR product was
generated from mouse tumour cDNA, spanning from the 59UTR
to exon 5 (primers were 59-CTGCTCTCTGCTCCCAGTCT-39
and 59-GGACGTCTGTGAGAGCAT-39) and cloned into
pGem3Z. For CD44, a 446 bp long PCR product spanning the
ﬁnal four exons (which are common in all transcripts) was
generated from mouse tumour cDNA, (primers were 59-
GGCTCCTTACCAGGAGATCG-39 and 59-CGTAGGCACTA-
CACCCCAAT-39). For hybridisation control, a b-actin probe
(414 bases) was used. Riboprobes were generated by in vitro
transcription using SP6 polymerase and labelled with
35S-UTPor
3H-UTP (GE Healthcare, Chalfont St Giles, UK). Other methods
were as described by Poulsom et al.
21 Signal intensity for assays
using
35S-UTP labelled probes was scored in at least 10 polyps
from each type of mouse (by SS and AL) blinded to polyp origin,
as long as the b-actin signal passed a quality control threshold.
Total expression was calculated as the proportion of the
epithelial component of a polyp that expressed the mRNA of
interest. This was done by capturing simultaneous bright ﬁeld
and dark ﬁeld images for each adenoma and using the ImageJ
software package to measure the total area of the epithelial
component of the adenoma and the area showing mRNA
expression. A ratio was calculated from these areas to give the
proportion of expressing cells. For Lgr5, where mRNA expression
intensity differed between 1322T and Min lesions, that propor-
tion was multiplied by the estimated mean intensity of the test
mRNA measured on a semiquantitative scale from 0 to 3
(absent¼0, weak¼1, moderate¼2, strong¼3) compared with
b-actin control and with reference to surrounding normal tissue.
In
3H-UTP-based assays 135 normal crypts of each genotype
were scored for the number of positive cells ($4 silver granules
present).
Immunohistochemistry
Immunohistochemistry was carried out using 4 mm sections
from the same formalin-ﬁxed parafﬁn-embedded tissues used for
ISH. Sections were dewaxed, hydrated, blocked with hydrogen
peroxide and antigen retrieval was carried out by microwaving
in sodium citrate buffer for 10 min. Normal goat serum diluted
to 1:1250 in 1% BSA was used as a blocking agent for 30 min.
The following primary antibodies were added for 1e4 h: poly-
clonal rabbit anti-Bmi1 antibody (Abgent, AP2513b) diluted to
1:150 or polyclonal rabbit anti-musashi antibody (Chemicon,
AB5977) 1:200. Bmi1 stained sections were washed in PBS before
applying a secondary antibody (biotinylated goat anti-rabbit
DAKO, 1:1250) for 1 h at room temperature. Sections were
washed in PBS and incubated in ABC (Vector Laboratories,
Burlingham, CA, USA) for 30 min before washing. 3,3’-diami-
nobenzidine (DAB) solution (Sigma) was applied for 2e5 min
and development of the colour reaction was monitored micro-
scopically. Slides were washed in PBS, stained with a light
haematoxylin, dehydrated, cleared and then mounted using Di-
n-butyl phthalate in Xylene (DPX). Msi1 stained sections were
incubated with secondary antibody (molecular probes goat anti-
rabbit Alexa 488, 1:300 dilution) for 1 h, immersed in Sudan
black (0.1% in 70% IMS) to reduce the autoﬂuorescence of
parafﬁn sections and mounted in hard set VECTAMOUNT
(Vector Laboratories) with 4’, 6-diamino-2-phenylindole (DAPI).
Positive cells were scored as present or absent in at least 10
polyps from each type of mouse by MD while blinded to polyp
origin.
Statistical analysis
KruskaleWallis and Wilcoxon non-parametric tests were carried
out using the STATA 9.0 package, Student t tests were carried
out in Excel and the microarray analysis was carried out using R,
as described above.
RESULTS
Our previous ﬁndings showed that adenoma numbers and size
were greater in mice carrying a 1322T mutation than in those
with a Min mutation. This differential phenotype has remained
stable in 1322T animals from 10 to >20 generations of back-
crossing with C57Bl/6J. We have conﬁrmed it is due to the
location of the Apc truncating mutation by intercrossing the
two strains and showing segregation of the more severe
phenotype with the 1322T genotype. Polyp numbers were
signiﬁcantly higher and polyps larger in the F1 1322T mice than
in the Min. Overall, however, the numbers of polyps caused by
both 1322T and Min mutations fell after the intercross,
suggesting selection for recessive positive modiﬁers and consis-
tent with informal observations that inbreeding increases the
severity of both the 1322Tand Min phenotype.
Levels of nuclear b-catenin and active b-catenin were consis-
tently lower in 1322T than in Min adenomas.
4 We wondered
whether this would result in lower levels of Wnt target gene
expression in the former. We therefore carried out mRNA
expression proﬁling using exon microarrays in enterocytes from
three Min and three 1322T adenomas of similar size from the
SB2 region of the small intestine. Since 1322T tumours contain
high frequencies of Paneth cells, which appear to be terminally
differentiated and hence not to be progenitors of tumour
growth, we used laser capture microdissection to exclude this
lineage from the analysis. Figure 1A shows the Wnt pathway
target genes (http://www.stanford.edu/wrnusse/pathways/
targets.html) that are differentially expressed (fold change >1.3)
between the two strains. As expected, there are more Wnt
targets upregulated in Min than in 1322Tadenomas (p¼0.0003,
sign test; see table 1 in the online supplement for results from all
Wnt target genes, ﬁgure 1A in the online supplement for
expression levels of differentially expressed genes and ﬁgure 2 in
the online supplement for further analyses of Wnt pathway and
target genes).
Selected signiﬁcantly different genes were then validated
using quantitative RT-PCR (Q-PCR) on both the original
samples and on a further independent microdissected sample set
of ﬁve 1322T and four Min tumours. Two of the more highly
expressed Wnt target genes with altered expression could be
validated (p<0.05, Student t test): Lgr5, a known intestinal stem
cell marker, which was upregulated by nearly threefold in 1322T
adenomas and wnt inhibitory factor 1 (Wif1) which was
increased by nearly fourfold in Min adenomas (ﬁgure 1B). Axin2
and Tcf7 were more highly expressed in Min samples, but not
signiﬁcantly. Other putative Wnt target genes from the Bmp
pathway (Bmp2, Bmp4, and Grem1) showed signiﬁcant
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Colon cancerexpression changes in our microarray, with Q-PCR analysis
demonstrating changes in the same direction to the arrays in all
cases although these were not formally signiﬁcant (see ﬁgure 1B
in online supplement). Q-PCR analysis is often unable to reli-
ably detect small (less than twofold) differences, especially when
there is some biological variability. Given the importance of the
Bmp pathway in stem cell regulation and colorectal cancer,
22 23
and the fact that three genes in this pathway show changes,
these small differences in expression could be biologically rele-
vant and should not be discounted.
We were particularly interested in the fact that Lgr5 expres-
sion was increased in 1322T tumours, because of its role as
a marker of intestinal stem cells and because the lower nuclear b-
catenin levels had led us to expect that Wnt target gene
expression would be lower in 1322T tissue. We therefore decided
to investigate the distribution of Lgr5 expression in more detail
using isotopic ISH on sections of intestinal adenoma. We found
that Lgr5 expression occurred in large patches in these tumours,
and that the patches were larger and more intense in 1322T
tumours than Min lesions of similar size (ﬁgure 2A,B, intensity
3 area, p¼0.0008; intensity, p¼0.004; area, p¼0.065; Wilcoxon
test). In general, Lgr5 expression in tumours was much more
extensive than in normal tissue where it was conﬁned to the
bottom of the crypts, as previously described.
8
We then determined whether stem cell numbers, as detected
by Lgr5 expression, might also differ between 1322T and Min
mice in normal tissues on the basis that this might play
a causative role in early microadenoma formation. Using
3H-labelled riboprobes to provide high resolution (ﬁgure 2C),
positive cells (deﬁned as those with $4 signals) were counted in
normal crypts in 1322T, Min and wild-type samples. Only full-
length longitudinally orientated crypts with identiﬁable cell
types >10 crypts away from tumour tissue were included in the
study. The high resolution and sensitivity of this assay meant
that we were able to detect Lgr5 expression in most crypts and
conﬁrm that Lgr5-positive cells are found in the base of the
crypt, usually in the CBC position. A small but signiﬁcant
(p¼0.002, KruskaleWallis test) difference between strains was
detected, with an increased number of Lgr5-positive cells
occurring in 1322T but not in Min crypts compared with wild-
type mice (ﬁgure 2D). An additional beneﬁt of the high resolu-
tion ISH was that we were able to conﬁrm that the large
majority of Paneth cells in both 1322T and Min tumours and
normal tissues were not positive for Lgr5 expression, ruling out
the possibility that a change in cellular composition was the
reason for the high levels of Lgr5 detected by standard ISH in
1322T tumours (see ﬁgure 3 in online supplement).
These data, together with our observation of an increase in
crypt ﬁssion in 1322T tumours,
4 suggested that a reason for the
more severe phenotype in 1322T mice was an increased number
of stem cells in both normal tissues and early tumours. To
provide further evidence for this hypothesis, we carried out
analyses of other intestinal stem cell markers by immunohis-
tochemistry (IHC) or ISH. For Bmi1 we found only a small
number of cells which showed expression in normal tissue,
many fewer than we identiﬁed in the Lgr5 ISH experiments and
too few to conduct a meaningful analysis in normal crypts.
However, in tumours there were signiﬁcantly more Bmi1-posi-
tive putative stem cells in 1322T than Min adenomas
(p¼0.0001, Wilcoxon test, ﬁgure 3A). Msi1 expression was
observed in a similar number of adenoma cells to Bmi1 and was
again signiﬁcantly more prevalent in 1322T tumours (p¼0.0011,
Wilcoxon test, ﬁgure 3B). Cd44, also a putative stem cell marker
for mouse tissue (ﬁgure 3C). Expression of Cd44 was much more
widespread in tumours than Bmi1 and Msi1 and was found in
the same cell populations as Lgr5 as well as additional areas,
staining virtually all cells in 1322T tumours but with a more
patchy pattern in Min tumours (p¼0.0212). Q-PCR analysis
conﬁrmed the upregulation of Cd44 in 1322T tumours (see
ﬁgure 1 in online supplement).
Since all the stem cell markers we investigated showed an
increase in 1322T tumours, we assessed whether the increase in
stem-like cells was consistent with the faster growth of
adenomas seen in 1322T mice. To do this, we carried out
mathematical modelling using our model based on tumorigen-
esis by failure of differentiation of stem cells (see ﬁgure 4 in
online supplement).
24 We mimicked the differences between
1322T and Min animals by assuming that the probability of
a stem cell undergoing differentiation was slightly lower on the
1322T than the Min genetic background. Even small differences
in this probability gave profound differences in the rate of cell
expansion and thus could account for the differences between
the 1322Tand Min phenotypes.
DISCUSSION
Adenomas in Apc
1322T mutant mice are larger, more numerous
and of earlier onset than those from Apc
Min animals in which the
mutant protein is truncated at codon 850 and lacks all b-catenin
binding repeats. We have previously shown that adenomas from
1322T mice have lower nuclear b-catenin than Min adenomas.
Here we found, as predicted, that lower levels of b-catenin are
Figure 1 Differential expression of Wnt target genes. RNA extracted
from laser captured microdissected tissue from three 1322T and three
Min adenomas was analysed using exon arrays (Affymetrix) and
differentially expressed Wnt targets were determined using the R
statistical package with Bioconductor and LIMMA tools. (A) Graph
showing fold changes of differentially expressed Wnt targets (fold
change >1.3) with genes upregulated in Min shown above the x-axis
and 1322T below. Highly signiﬁcant differential genes (p<0.01) are
marked with an asterix. (B) Graph showing differentially expressed
genes validated by Q-PCR analysis (*p<0.05). The housekeeping gene
Gapdh was used as a normalisation control and the fold change was
calculated using the ΔΔCt method.
Gut 2010;59:1680e1686. doi:10.1136/gut.2009.193680 1683
Colon canceraccompanied by generally lower expression of Wnt pathway
genes, including the Wnt inhibitory factor Wif1. However, stem
cell markersdincluding both Wnt targets such as Lgr5 and Cd44
and non-Wnt targets such as Bmi1 and Msi1dare upregulated in
1322T tumours compared with Min tumours. This suggests that
the levels of Wnt signalling resulting from the homozygous
1322T mutation found in tumours are closer to the optimum for
promoting expression of genes that cause the stem cell pheno-
type than are the Wnt levels found in Min tumours. The stem
cell phenotype is thus favoured by submaximal Wnt signalling.
We observed subtle differences in the numbers of cells
expressing Lgr5 in normal tissue prior to tumour initiation,
suggesting that haploinsufﬁciency of Apc has a detectable effect
on stem cell numbers. This effect may explain some of the
differences in tumour initiation if, according to the cancer stem
cell model of tumorigenesis, the tumour-causing ‘second hit’ ﬁrst
occurs in a stem cell and then spreads by clonal expansion.
However, a much larger variation in stem cell number occurs in
tumours of the same size and location between mouse strains
than can be explained by this effect alone. Tumour progression
must therefore differ as well, and cells which already have
a second hit at codon 1322 favour Lgr5 expression and stem cell
characteristics.
More than half of the epithelial portion of the 1322T
adenomas showed Lgr5 and/or Cd44 expression which could
indicate that all these cells are (cancer) stem cells. While this is
possible, it is more likely that these cells have some stem cell-like
characteristics such as the ability to self-replicate, or that these
cells have the potential to be stem cells given the right local
conditions or niche. It is notable that Bmi1 and Msi1 protein
expression was detected in far fewer cells overall. While some of
these differences may be explained by technical factors such as
threshold levels of detection for ISH and IHC as well as
differences between the levels and stability of the respective
mRNAs and proteins, it may be that there are different and
dynamic populations of stem-like cells that express different
markers at different points in time. We must also consider that
the presence of stem cell markers does not necessarily mean that
all the cells they mark function as stem cells or cancer stem cells
in vivo. There is currently no straightforward functional assay
that identiﬁes stem cells, but lineage tracing experiments in
reporter micedpossibly in conjunction with allograft studies
using tumour stem cells from 1322Tand Min animalsdcould be
used in the future to identify which marker or marker combi-
nation most accurately deﬁnes the stem cell population.
Although high levels of expression of the target gene Lgr5
indicate increased stem cells in 1322Tadenomas, the functional
role of the Lgr5 protein itself still remains unclear. It is therefore
likelythat other primaryor secondary Wnt targets areimportant.
Another Wnt pathway gene, Wif1, was differentially expressed,
with higher levels in Min tumours. While not previously known
to play a major role in colorectal cancer, Wif1 expression has been
Figure 2 1322T normal and adenoma
tissue contains more Lgr5-positive cells.
Lgr5 ISH was carried out on 4 mm
sections of formalin-ﬁxed parafﬁn-
embedded 1322T and Min intestines.
(A) Bright ﬁeld images (103 objective
magniﬁcation) of tumours showing
patches of Lgr5 expression (visualised
by silver granules) and counterstained
with Giemsa. The signal is more
widespread and more intense in the
1322T adenoma. (B) Box and whiskers
diagram showing increased Lgr5
staining scored in 1322T and Min
polyps (n¼10 for each genotype). For
each polyp the area of staining was
calculated as a proportion of the whole
epithelial component and multiplied by
the estimated mean intensity of the test
mRNA. 1322T adenomas were scored
much higher than Min (p¼0.0008,
Wilcoxon test). (C) Bright ﬁeld images
of in situ hybridisation carried out using
a
3H-labelled Lgr5 probe at 603
magniﬁcation showing normal crypt
tissue. Positive cells are outlined.
Enlargements of selected cells are
shown in the bottom panel. More
expression can be seen in 1322T crypts
than in Min and wild-type crypts. (D)
Box and whiskers plot showing that
more Lgr5-positive cells were present in
1322T crypts than in Min and wild-type
normal crypts (p¼0.002,
KruskaleWallis test); 135 crypts of
each genotype were scored for the
number of positive cells ($4 silver
granules present). In most cases
positive cells were crypt base columnar cells, but occasionally a Paneth cell or cell in the +4 position also showed some Lgr5 expression.
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Colon cancershown to inhibit bladder tumour growth and osteosarcomas and
is often silenced by methylation in breast carcinomas and colo-
rectal cancer cell lines.
25e28 Wif1 is unlikely to be a direct Wnt
target gene, but it has been proposed that it acts as part of
a negative feedback loop.
29 Wif1 expression could potentially play
a role in the Min adenomas, repressing tumour growthdperhaps
by repressing the stem cell phenotypeddespite high levels of
nuclear b catenin and Wnt signalling. In support of this, Wif1
expression is generally low or absent in familial adenomatous
polyposis tumours.
30 Since it is counterintuitive that the feed-
back effect of Wif1 is stronger than the Wnt signal, it is necessary
to postulate additional factors such as selective downstream
effectsforWif1toplayaroleincausingthephenotypicdifferences
between the 1322Tand Min animals.
Our expression arrays showed a small increase in expression of
several other Wnt targets in 1322T adenomas including EphB2,
EphB3, Grem1, Mmp7 and Myc. Unlike Lgr5, these increases were
not validated by Q-PCR, possibly due to the large variability
between tumours, but they may still give us further insights
into the mechanisms leading to tumorigenesis or increased stem
cell number. The Grem1 gene is normally expressed in subepi-
thelial myoﬁbroblasts and found only at low levels in adenomas.
Interestingly, however, it is an inhibitor of TGFb/Bmp signal-
ling, a pathway that is proposed to inhibit stem cell renewal,
31
so higher levels of Grem1 expression, together with the lower
levels of Bmp2, Bmp4 and Bmp5 expression seen in 1322T
tumours, could contribute to the observed stem cell phenotype.
In addition, expression of the matrix metalloproteinase MMP7
correlates with poor prognosis in patients with colorectal cancer
and promotes tumorigenesis in Min mice.
32e34 It is also
expressed highly in Paneth cells which are over-represented in
1322T adenomas. Since Paneth cells lie within the normal
intestinal stem cell compartment, it is possible that MMP7 also
inﬂuences stem cell numbers. Similarly, the difference in Myc
expression, although small, could play an important role in
disease severity. Myc is essential for the phenotype caused by
Apc mutation in the intestine, and many of the genes upregu-
lated after Apc loss, including the EphB receptors, are dependent
on Myc expression.
35 It is more difﬁcult to explain the role of
EphB in the severe 1322T phenotype. EphB signalling is impor-
tant for cell compartmentalisation and migration in the intes-
tine,
36 but it is thought that high levels limit the expansion of
adenomas.
37 However, the expression of the EphB genes is
highest at the base of intestinal crypts in normal tissue, with
EphB3 restricted exclusively to the region containing the stem
cells, which could explain the high levels found in the stem cell-
rich 1322T tumours.
Our use of mouse models in this study has allowed us to
analyse in detail the effect of the location of speciﬁc germline
and somatic Apc mutations to test the ‘just right’ hypothesis.
Both our strains were kept on identical genetic backgrounds and
no confounding mutations were seen at the loci. In addition, we
have excluded the existence of unlinked modiﬁers in our mouse
models by intercross experiments. While it is difﬁcult to
Figure 3 Stem cell markers are
generally increased in 1322T adenomas.
(A) Immunohistochemistry carried out
with anti-Bmi1 antibody on 1322T and
Min adenomas shown at 203 objective
magniﬁcation. Box and whiskers
diagram showing more Bmi1-positive
cells were present in 1322T adenomas
than in Min adenomas (n¼14 for each
genotype, median 7.5/1000 compared
with 2.5/1000 in Min polyps; p¼0.0001,
Wilcoxon test). (B) Fluorescent
immunohistochemistry carried out with
anti-Msi1 antibody on 1322T and Min
adenomas shown at 203 objective
magniﬁcation. Box and whiskers
diagram showing more Msi1-positive
cells were present in 1322T adenomas
than in Min adenomas (n¼10 for each
genotype, median of 8.5 cells/1000
counted in the 1322T adenomas
compared with 2.5 cells/1000 in Min
adenomas matched for location and
size; p¼0.0011, Wilcoxon test). (C)
Isotopic in situ hybridisation carried out
with CD44 riboprobe on 1322T and Min
adenomas shown at 203 objective
magniﬁcation in dark ﬁeld. Silver
granules stain areas of CD44
expression. Box and whiskers diagram
showing a larger area staining positive
for CD44 in 1322T adenomas than in
Min adenomas (n¼13 for 1322T and
n¼9 for Min, median area of 44%
showing staining in 1322T adenomas
compared with 35% in Min adenomas).
For each polyp the area of staining was
calculated as a proportion of the whole epithelial component using ImageJ software.
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in cis, an independent targeting event resulted in the same
phenotype as our 1322T model,
4 suggesting that the targeted
mutation alone is responsible for the severe polyposis and
characteristic distribution of adenomas.
Conﬁrmation of these results in samples from human patients
has, however, proved difﬁcult. As a result of the observations in
human familial adenomatous polyposis adenomas which led to
this hypothesisdnamely, that a germline mutation early in APC
is very rarely accompanied by an early somatic muta-
tiondsuitable samples to carry out analyses on patients with
familial adenomatous polyposis are not available. In general,
however, increased Lgr5 expression is seen in all familial adeno-
matous polyposis adenomas and the levels of nuclear b-catenin
are very low (see ﬁgures 5 and 6 in online supplement),
comparable to 1322T adenomas and consistent with the ‘just
right’ hypothesis.
Clearly, many questions remain about how the expression of
Wnt targets depends on nuclear b-catenin levels and other
factors in both normal and tumour tissues. Some Wnt target
genes known to be involved in intestinal tumorigenesis showed
no signiﬁcant difference between our two mouse models. For
instance, no change was seen in Tcf1 expression which has been
shown to suppress tumorigenesis in mammary tissue and also in
the intestines of Min mice.
38 We suggest that simple linear
dependence of target levels is unlikely, and that different targets
respond differently to changes in Wnt signalling. Our data
conﬁrm the operation of the ‘just right’ model of intestinal
tumorigenesis
12and suggest that it acts through promoting the
stem cell phenotype, although the underlying causes for the
strong selective constraints on APC mutations in colorectal
cancer are likely to be complex.
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